New Phase 3 Trial Approved for Masitinib for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxMevrometostat Update: a New Phase 3 Trial for mCSPC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 Trial: Ifinatamab Deruxtecan (MK-2400) for metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 ENZAMET Trial: Follow-up Data After 8 Years
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTALAPRO-2 Trial: Final OS Analisys Confirms Talazoparib + Enzalutamide Effectiveness in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPT-112: FDA Clears Phase 3 Trial of Novel Therapy for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Newsletter 30/2025 July 27, 2025
- New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets July 26, 2025
- Scientists Trace Deadly Shift in Prostate Cancer to Two Key Genes July 26, 2025
- Low-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising July 25, 2025